Regeneron to Acquire 23andMe for $256M
Regeneron Pharmaceuticals has agreed to acquire 23andMe’s consumer genetics business and assets for $256 million, following 23andMe’s Chapter 11 bankruptcy.
More Videos
Meta and Microsoft Just Sent a Big AI Message to Investors
Big Tech is pouring billions into AI. Ray Wang, CEO of Constellation Research, explains what Meta and Microsoft's earnings reveal about those investments.
Can NYC Finally Cool Its Subway?
Why is the NYC subway platform so hot? One rider built his own sensor network to find out. We explore the geothermal fix the MTA is piloting right now.
Boeing's Big Test: Earnings, Deliveries, and the Road Ahead
Morningstar equity analyst Nicolas Owens explains Boeing's latest earnings, deliveries, rising fuel costs, and what they mean for airlines and investors.
Inside Five Star Franchising's Plan to Help the Next Generation of Business Owners
Five Star Franchising CEO Scott Abbott explains why Millennials and Gen Z are embracing franchise ownership and what it means for the future of work.
Businesses Older Than America: 250+ Year Old Companies Still Going Strong
These three American businesses existed before the country itself, and they're still thriving!
The World Cup Isn't Just a Tournament, It's a $41 Billion Business
The 2026 FIFA World Cup is more than just a tournament. With over 6.5 million fans expected to attend, it's become one of the world's largest economic events.
